Q1 EPS Forecast for Dianthus Therapeutics Lifted by Analyst

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities researchers at HC Wainwright raised their Q1 2025 earnings estimates for shares of Dianthus Therapeutics in a research report issued on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.03) for the quarter, up from their previous estimate of ($1.21). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

Other research analysts have also recently issued reports about the stock. TD Cowen started coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $21.97 on Monday. Dianthus Therapeutics has a 1 year low of $18.13 and a 1 year high of $33.77. The stock has a market cap of $650.25 million, a P/E ratio of -8.79 and a beta of 1.82. The firm has a 50-day moving average of $22.44 and a 200 day moving average of $24.76.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $556,000. Barclays PLC grew its stake in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the period. HighVista Strategies LLC bought a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $542,000. State Street Corp grew its stake in shares of Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after acquiring an additional 97,362 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.